



Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer's Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in-development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models.

Dapansutrile (OLT1177)


Evidence Summary

This NLRP3 inflammasome inhibitor has oral bioavailability and good short-term safety, but no long-term data. It reduces IL-1 β mediated peripheral inflammation and is best suited to earliest disease stages.

Neuroprotective Benefit: Dapansutrile may decrease IL-1 β mediated inflammatory damage by preventing the metabolic reprogramming of immune cells toward a pro-inflammatory state and infiltration of peripheral immune cells into the CNS.

Aging and related health concerns: Based on short clinical studies, dapansutrile may reduce acute arthritis or gout-associated pain and inflammation. Benefits are most apparent when given prophylactically or at injury onset to prevent inflammatory damage.

Safety: Dapansutrile has not been associated with adverse events in acute studies, but long-term studies with chronic dosing have not been conducted. Possible increased risk for infection.

Availability: In clinical trials	Dose: Not established	Chemical formula: C ₄ H ₇ NO ₂ S MW: 133.17 g/mol  Source: PubChem
Half-life: ~24 hours (in plasma)	BBB: Penetrant	
Clinical trials: Phase 1 trials in healthy adults (n=36, n=35), a Phase 1b trial in heart failure (n=30), and Phase 2 trials in osteoarthritis (n=202, n=79, n=29) have been completed.	Observational studies: None	

What is it?

Dapansutrile is an **inhibitor of the NLRP3 inflammasome** being developed for inflammatory conditions as OLT1177™ by Olatec Therapeutics. The NLRP3 inflammasome is activated in response to various danger signals, such as pathogen-associated molecular patterns (PAMPs) released by microbial agents and damage-associated molecular patterns (DAMPs) released by stressed cells [1]. The activated NLRP3 inflammasome then promotes caspase-1 dependent production of the inflammatory cytokines IL-1β and IL-18, as well as a form of programmed cell death called pyroptosis. The activation of the NLRP3 inflammasome is a two-step process involving a priming signal that leads to the upregulation of NLRP3 and pro-IL1β, and a second signal which induces oligomerization and activation. Dapansutrile acts by inhibiting the second part, thereby preventing NLRP3 inflammasome oligomerization and the release of mature IL-1β, without affecting *nlrp3* or *il1b* gene expression [2]. Dapansutrile can also reduce levels of the pro-inflammatory cytokine IL-6 since IL-1β is a known inducer of IL-6 [3], but typically does not affect levels of TNFα. Dapansutrile does not affect the activity of related inflammasomes NLRC4 or AIM2 [2], and is thought to be specific for NLRP3, though more work is needed to confirm the specificity *in vivo*. Dapansutrile satisfies Lipinski's rule of five ([IUPHAR/BPS](#)), and has been shown to have good oral bioavailability in humans [2]. It has been tested in clinical trials in a topical gel formulation for osteoarthritis, and as an oral capsule formulation for gouty arthritis, and for heart failure. Olatec holds patents for using dapansutrile as a treatment for inflammatory skin conditions, inflammation and pain, and multiple sclerosis.



Neuroprotective Benefit: It may decrease IL-1 β mediated inflammatory damage by preventing the metabolic reprogramming of immune cells toward a pro-inflammatory state and infiltration of peripheral immune cells into the CNS.

Types of evidence:

- 5 laboratory studies

Human research to suggest prevention of dementia, prevention of decline, or improved cognitive function? None

Human research to suggest benefits to patients with dementia: None

Mechanisms of action for neuroprotection identified from laboratory and clinical research:

Activation of the NLRP3 inflammasome is implicated in driving IL-1 β mediated inflammation and pyroptotic cell death in a variety of neurodegenerative diseases, and NLRP3 inhibition has been shown to be protective in various preclinical models [4] (see NLRP3 Inhibition report). The NLRP3 inflammasome is abundantly expressed by microglia and astrocytes, and plays a role in innate immune responses in the CNS [4]. The NLRP3 inflammasome is activated in response to oxidative stressors, and chronic activation may play a role in the programming of microglia toward a hyperactive state associated with increased release of pro-inflammatory cytokines [5]. Mitochondria-related pathology can induce a shift from oxidative phosphorylation, which promotes tolerogenic (non-reactive) microglia toward aerobic glycolysis, which is associated with oxidative stress and promotes pathogenic microglia. NLRP3 inhibition, then, can reduce the inflammatory response associated with chronic mitochondrial stress. A study examining the effect of systemic administration of dapansutrile in mice found that treatment increased flux through the pentose phosphate pathway and promoted mitochondrial metabolism in muscle tissue [2]. This suggests that dapansutrile may potentially also help correct the metabolic impairment that is driving the induction of pro-inflammatory reactive glia. However, is not clear whether dapansutrile is the optimal NLRP3 inhibitor for neurodegenerative diseases.

Alzheimer's disease: POTENTIAL BENEFIT AT EARLY STAGES (Preclinical)

Brain and serum levels of IL-1 β have been shown to be elevated in Alzheimer's disease (AD), and some studies show an association with disease progression [6; 7]. In APP/PS1 AD model mice, treatment with dapansutrile (7.5 g/kg chow or ~ 1000 mg/kg/d) for three months, starting at six months of age, when



A β accumulation and neurological deficits are already present, reduced impairments in learning and memory, based on Morris water maze performance [8]. This was accompanied by the restoration of synaptic plasticity, including LTP induction and dendritic spine density. Treatment also reduced A β plaque load, and mitigated the neuroinflammatory response, including the pro-inflammatory cytokines IL-1 β , IL-6, and TNF α . These effects may stem from the ability of dapansutrine to prevent the metabolic reprogramming of immune cells, such as microglia, toward a state of pro-inflammatory activation, in response to A β -related stress. Consistent with this hypothesis, dapansutrine treatment normalized the metabolic profile in the AD mice, which shows evidence of mitochondrial dysfunction and altered fatty acid metabolism, based on plasma metabolomic analysis. These data suggest that dapansutrine is best suited toward the mitigation of inflammatory damage, thus it is likely to be most effective at the earliest stages of disease, to prevent neuronal damage, and may offer only marginal benefit once neuronal loss has occurred.

Spinal cord injury: POTENTIAL BENEFIT WITH EARLY INTERVENTION (Preclinical)

Levels of IL-1 β and IL-18 in the CNS are very low under normal physiological conditions, but increase following injury due to the influx and activation of immune cells [9]. Levels of the downstream cytokine effectors of NLRP3 activation, IL-1 β and IL-18 were found to be elevated following spinal cord injury in female mice [9]. At a dose of 200 mg/kg (i.p. once daily for 7 days) starting one-hour post-injury, mice treated with dapansutrine had greater preservation of hindlimb mobility, with 75% exhibiting stepping behavior, compared to 6% in the untreated group. This was accompanied by better survival of neurons in the injured region, as well as lower levels of active IL-1 β and caspase-1. In response to the reduction in IL-1 β , dapansutrine-treated mice also had lower infiltration of neutrophils and macrophages into the spinal cord, which may account for the mitigation of secondary damage to spinal cord neurons. Since these inflammation-related secondary damage processes begin within hours of the original injury, the timing of administration may be critical for therapeutic efficacy. However, since IL-18-related inflammation shows a delayed time course relative to IL-1 β , later stage treatment may still offer some neuroprotective benefits.

Multiple sclerosis: POTENTIAL BENEFIT (Preclinical)

Dapansutrine was tested in a mouse model of chronic experimental autoimmune encephalomyelitis (EAE) induced by active immunization with a MOG peptide, a myelin-associated protein [10]. When administered prophylactically in the diet (3.5 g/kg food) starting at the time of immunization, dapansutrine reduced the infiltration of CD4+ T cells and macrophages into the spinal cord, as well as spinal cord levels of the pro-inflammatory cytokines IL-1 β , IL-18, and IL-6. This was accompanied by a 2-



fold reduction in spinal cord demyelination, and a reduction in neurological deficits. When administered as a treatment starting at the onset of neurological symptoms, dapansutrine was also protective, but only with twice daily administration (60 mg/kg i.p. or oral gavage). This study suggests that NLRP3 inhibition with dapansutrine may be beneficial at reducing CNS pro-inflammatory cytokines derived from peripheral sources. This is likely due to its effects on IL-1 β , which is known to play a role in BBB permeability [11].

Parkinson's disease: POTENTIAL BENEFIT (Preclinical)

In an acute mouse model of Parkinson's disease, dapansutrine (200 mg/kg i.p. 1 hour prior to MPTP) protected against MPTP-induced motor deficits, alpha-synuclein aggregation, dopaminergic cell loss, and mitigated the striatal elevations of the NLRP3-related pro-inflammatory cytokines IL-1 β and IL-18 [12]. Treatment with dapansutrine also reduced MPTP-induced reactive gliosis and preserved levels of the non-glycosylated form of TREM2 in the striatum. Further studies are needed to determine whether dapansutrine is effective in other models of the disease, particularly when administered after cell loss has already occurred.

Olatec Therapeutics announced that it will conduct a Phase 2 trial testing the ability of dapansutrine (OLT1177[®]), to slow disease progression in patients with early Parkinson's disease. Based on the [press release](#), they plan to enroll 36 patients for a six-month placebo-controlled study, followed by a six-month open label phase. The study is being funded by a grant from Cure Parkinson's. To date, the trial has not yet been initiated.

Hemorrhage: POTENTIAL BENEFIT (Preclinical)

Dapansutrine, administered 200 mg/kg i.p. at 1, 24, and 48 hours after induction of experimental intracerebral hemorrhage via injection of autologous blood into basal ganglia, attenuated the development of cerebral edema in male (C57Bl/6) mice [13]. Dapansutrine preserved the integrity of the BBB, and protected against neuronal loss. Dapansutrine mitigated the induction of neurological deficits based on modified Garcia scores, and better motor coordination on the rotarod and cylinder tests. The protective effects may have been partially mediated by preventing the induction of a pro-inflammatory phenotype in the microglia in response to the hemorrhage. Further studies are needed to determine whether there is a therapeutic window of administration, whether dapansutrine can impact the chronic phase of intracerebral hemorrhage, or if the protective effect is diminished in elderly animals.

APOE4 interactions: Not known



Aging and related health concerns: Based on short clinical studies, it may reduce acute arthritis or gout-associated pain and inflammation. Benefits are most apparent when given prophylactically or at injury onset to prevent inflammatory damage.

Types of evidence:

- 4 clinical trials (2 Phase 2 RCTs for knee osteoarthritis n=79, n=202; 1 Phase 2 open-label trial in gouty arthritis n=29; 1 Phase 1b pilot trial in heart failure n=30).
- Several laboratory studies

Osteoarthritis: POTENTIAL BENEFIT

Osteoarthritis is associated with joint pain following the degeneration of protective cartilage ([Mayo Clinic](#)). It is a non-autoimmune form of arthritis, and the risk for developing osteoarthritis increases with age.

A topical gel formulation of dapansutril has been tested in two placebo-controlled Phase 2 RCTs in patients with knee osteoarthritis. The results of these trials have not been posted, but according to the Olatec [website](#), patients treated with dapansutril in both the 2-week dose finding study (n=79, gel administered TID) ([NCT01768975](#)) and the 6-week study (n=202, 6 mL of 5% gel administered TID) ([NCT02104050](#)) exhibited a reduction in knee pain at a level considered to be clinically meaningful based on the literature [14]. However, these trials were completed in 2013 and 2015, respectively, and but full results have not been made publicly available.

In a medial meniscus resection-based rat model of osteoarthritis, the intra-articular injection of dapansutril to the knee joint once per week post-surgery for four weeks protected against cartilage degeneration, with the animals showing less damage on the Mankin's score and Osteoarthritis Research Society International score [15]. In cultured chondrocytes, dapansutril dose-dependently downregulated the expression levels of the phospho-ERK, and phospho-P38, mediators of pro-inflammatory signaling cascades [15].

Gouty arthritis: POTENTIAL BENEFIT

Gout is a form of arthritis that develops due to the buildup of uric acid crystals in the joints ([Mayo Clinic](#)). It is typically associated with the release of pro-inflammatory cytokines by cells of the synovial lining and an associated infiltration of neutrophils into the joint cavity [16]. The NLRP3 inflammasome has been found to be involved in gout-associated inflammation, and IL-1 inhibitors are currently approved for the treatment of gout.

An oral formulation of dapansutril has been tested in an open-label Phase 2a proof-of-concept study in patients with acute gout flares (n=29) ([EudraCT Number: 2016-000943-14](#)). Participants were treated with dapansutril in a dose-adaptive manner (100 mg/day, 300 mg/day, 1,000 mg/day, or 2,000 mg/day) for eight days [17]. The co-primary endpoints were change in patient-reported target joint pain from baseline to day 3 and from baseline to day 7. The mean reductions in patient-reported joint pain were $52.4\% \pm 32.94\%$, $68.4\% \pm 34.29\%$, $55.8\% \pm 44.90\%$, and $57.6\% \pm 38.72\%$ at day 3, and $82.1\% \pm 22.68\%$, $84.2\% \pm 16.33\%$, $68.9\% \pm 34.89\%$ and $83.9\% \pm 15.44\%$ for the 100 mg/day, 300 mg/day, 1,000 mg/day, and 2,000 mg/day groups, respectively. General disability and walking disability also declined in all groups. Although there were no significant differences between groups, there was a dose-dependent decrease in investigator-assessed joint inflammation, with those in the 100 mg/day group showing only a marginal decrease in inflammation. Plasma IL-6 levels declined in all but the 100 mg/day group. There were no significant changes in plasma IL-1 β , IL-18, or TNF α levels, but there was a significant reduction (44-45%) in *ex vivo* stimulation-induced IL-1 β production in peripheral blood mononuclear cells (PBMCs) from patients in the higher dose groups. Without a placebo control, the magnitude of the effect is unclear. Larger studies are needed to determine whether dapansutril offers clinically meaningful benefit in this population.

An associated mechanistic study found that markers of inflammation, C-reactive protein and serum amyloid A, were dose dependently decreased over the seven-day treatment course [18].

Dapansutril (600 mg/kg) also reduced joint inflammation in a mouse model of gouty arthritis (monosodium urate injection), when administered prophylactically or one hour following the urate injection [16]. Treatment reduced inflammatory immune cell infiltration and synovial levels of pro-inflammatory cytokines and chemokines (IL-1 β , IL-6, MPO, CXCL1). Notably, the plasma levels of dapansutril associated with efficacy in the mice were within range of the plasma levels in humans after oral intake of doses found to be safe in a Phase 1 study.

Dapansutril is currently being tested in a randomized, double-blind, placebo-controlled Phase 2/3 trial (estimated n=300) in patients with acute gout flare ([NCT05658575](#)).

Heart injury: POTENTIAL BENEFIT

NLRP3 inflammasome activation in the context of a heart ischemic-reperfusion injury can activate caspase-1 mediated pyroptotic cell death and promote the loss of myocardial tissue [19]. Dapansutril was tested in a randomized, double-blind Phase 1b trial ([NCT03534297](#)) at doses of 500, 1,000, or 2,000 mg/day (five oral capsules once, twice, or four times per day) for up to 14 days in patients with NYHA II–III defined systolic heart failure (n=30) [20]. A placebo group was included to reduce bias, but the n's (n=2 per dosing cohort) were too small for statistical comparison. In the dapansutril-pooled group,

there was no significant change in systolic blood pressure over the 12±2 days of treatment, but a significant increase in systolic blood pressure in the placebo-pooled group. There were no significant changes in diastolic blood pressure or heart rate in either the dapansutrine or placebo groups. There was a significant decrease in fasting plasma glucose from baseline in the dapansutrine-pooled group (-10.5, 95% Confidence Interval [CI] -40 to 7 mg/dL). Although this trial was not powered to detect changes in functional parameters, an exploratory assessment of these measures is suggestive of benefit at the highest dose. There were improvements in left ventricular ejection fraction (from 31.5%, 95% CI 27.5 to 39% to 36.5%, 95% CI 27.5 to 45%) and in exercise time (from 570, 95% CI 399.5 to 627 seconds to 616, 95% CI 446.5 to 688 seconds) in the dapansutrine 2,000 mg cohort. There were no significant changes in quality-of-life measures (KCCQ and DASI scores), or systemic inflammatory markers (hsCRP or NT-proBNP). Overall, the results were consistent with what has been seen with IL-1 blockers in this population, and larger, controlled trials are needed to confirm clinical benefit.

In preclinical rodent models, IL-1 β can induce a heart failure phenotype, and dapansutrine treatment has been shown to help preserve some aspects of cardiac function following myocardial injury. While dapansutrine had no effect on heart contraction, based on left ventricular ejection fraction, in wild-type mice, it preserved left ventricle systolic function in mice examined 24 hours after myocardial ischemic-reperfusion injury [21]. Dapansutrine (600 mg/kg i.p.) was protective when administered at the time of reperfusion following both a short (30 minute) and long (75 minute) bout of ischemia, and when administered up to one hour after reperfusion. This suggests that dapansutrine may have a therapeutic window conducive to use in a clinical setting. The protective effect on heart function was associated with a ~50% reduction in caspase-1 activation and reduction in infarct size. In male mice with severe ischemic cardiomyopathy due to non-reperfused anterior wall myocardial infarction, dapansutrine (7.5 g/kg chow for 9 weeks starting 7 days after injury) had no significant effect on left ventricle ejection fraction, but significantly increased preservation of their contractile reserve, which is a measure of β -adrenergic responsiveness [22].

Dapansutrine is currently being tested in the Phase 2 Dapan-Dia trial ([NCT06047262](https://clinicaltrials.gov/ct2/show/study/NCT06047262)) to assess its ability to mitigate diabetes-related vascular complications in patients with type 2 diabetes.

Dapansutrine is also being tested in an early Phase 1 trial in which advanced cardiovascular imaging will be used to assess the impact of NLRP3 inflammasome inhibition on carotid plaque volume, inflammation, and microvascular function in patients with a type 1 myocardial infarction ([NCT05880355](https://clinicaltrials.gov/ct2/show/study/NCT05880355)).

Atrial fibrillation: In a rodent model of heart failure with preserved ejection fraction (HFpEF) in which Dahl salt-sensitive rats were fed a high (8%) salt diet, treatment with dapansutril (200 mg/kg/day via oral gavage) for four weeks starting at ten weeks of age attenuated cardiac inflammation and atrial fibrosis [23]. It also lowered the blood pressure in these animals. Notably, the dapansutril-treated rats were less prone to atrial fibrillation following electrical stimulation (30% vs 90%) by preventing electrical remodeling and maintaining calcium homeostasis in the cardiac tissue.

Melanoma: POTENTIAL BENEFIT TO AUGMENT IMMUNOTHERAPIES (Preclinical)

Comparison of melanoma (n=469) and healthy skin samples (n=324) from the TCGA and GTEx cancer genome datasets revealed that the expression of NLRP3 and IL- β were higher in melanoma samples, and that levels of NLRP3 and IL-1 β were highly correlated in the tumor tissue [24]. Tumor derived IL-1 β stemming from NLRP3 activation was found promote an immunosuppressive tumor microenvironment by inducing the expansion of myeloid-derived suppressor cells (MDSCs), and shifting the balance toward less cytotoxic CD8+ T cells and more immunosuppressive T regulatory cells [24]. Tumor progression was reduced in dapansutril-treated mice implanted with B16F10 melanoma cells [24; 25]. The effect was driven by the effect on the immune system rather than on tumor cell proliferation, and was dependent on tumor driven IL-1 β , as dapansutril also inhibited tumor growth in NLRP3 deficient mice with NLRP3+ tumors [24]. MDSCs contribute to a variety of immunosuppressive mechanisms, including the expression of immune exhaustion markers PD-1/PD-L1. In mice, dapansutril augmented the anti-tumor activity of anti-PD-1, suggesting it may be beneficial for overcoming anti-PD-1/PD-L1 resistance [24]. Dapansutril is currently being tested in an open-label Phase 1/2 trial in combination with pembrolizumab (anti-PD-1) in patients with PD-1 refractory advanced melanoma (NCT04971499).

The combination of a dapansutril-enriched diet (7.5 mg per kg of food) with dexamethasone (10 mg/kg i.p. every 3 days) synergized to reduce tumor growth in a model of implanted (2×10^5) B16F10 melanoma cells in wildtype (C57Bl/6) mice to a greater degree than either treatment alone [26]. The reduction in tumor growth may stem from a decrease in the phosphorylation of STAT3 at S727 and Y705 in the tumors with the combination treatment. The combination of dapansutril with dexamethasone also dampened the inflammatory induction of aerobic glycolysis (Warburg effect) in the tumor cells.

Pancreatic Ductal Adenocarcinoma (PDAC): POTENTIAL BENEFIT TO AUGMENT OTHER THERAPIES (Preclinical)

NLRP3 expression, along with downstream mediators, ASC, IL-1 β , and IL-18 were found to be increased in pancreatic tissue from patients with PDAC (n=179), relative to healthy pancreatic tissue (n=171) [27]. In an orthotopic model, in which mice were implanted orthotopically with murine PDAC FC1242 cells,

tumor growth was reduced in mice lacking NLRP3 as well as in mice fed a dapansutrine-enriched diet (7.5 mg per kg of food) [27]. This was associated with enhanced infiltration of effector CD8 T cells expressing CD44 and PD-1, and restored a Th1 immune response. Additionally, the combination of dapansutrine with the chemotherapeutic gemcitabine (50 mg/kg i.p. every 3 days) enhanced the anti-tumor efficacy of gemcitabine.

Colitis: UNLIKELY TO BENEFIT ESTABLISHED DISEASE (Preclinical)

Dapansutrine has been shown to protect against DSS-induced colitis in rodents when administered prophylactically, but not when administered therapeutically, after colon damage had been established [28]. When administered early, it reduced weight loss, histological damage, and pro-inflammatory cytokine levels (IL-1 β , IL-6, TNF α) in the colon of mice. Notably, dapansutrine minimized the induction of NF- κ B, the maturation of IL-1 β , and activation of caspase-1 when administered prophylactically or therapeutically, but only showed disease activity benefit in the context of the former. A separate study in rats also found that prophylactic treatment reduced immune cell infiltration and histopathological damage to the colon, but as a monotherapy had limited impact on oxidative stress [28]. This suggests that in the context of chronic colitis, dapansutrine may help limit the induction of further inflammatory damage, but would need to be used in combination with other strategies that could ameliorate the pre-existing damage and/or dampen the ongoing damage-inducing cascades.

Asthma: POTENTIAL BENEFIT (Preclinical)

Dapansutrine (60 mg/kg i.p. or 7.5 g/kg chow) mitigated the eosinophilic asthma endotype in multiple mouse models of asthma [29]. The reduction in airway inflammation was linked to the reduced infiltration of eosinophils and neutrophils into the lungs. Consistent with its mechanism of action, treatment decreased NLRP3 expression and caspase-1 activation in lung tissue, and levels of activated IL-1 β in broncho-alveolar lavage fluid. Dapansutrine appears most likely to be beneficial in protecting against acute exacerbations when used prophylactically.

Acute kidney injury: POTENTIAL MINOR BENEFIT (Preclinical)

When administered either prophylactically (prior to injury) or therapeutically (starting day of injury) dapansutrine (0.2 mg/kg i.p.) protected against folic acid-induced nephrotoxicity in male rats [30]. Kidney function was partially preserved, though still impaired relative to control animals, based on serum creatinine and urea levels. This was accompanied by significant reductions in IL-1 β , IL-18, and caspase-1.

Acute liver injury: POTENTIAL BENEFIT WITH PRETREATMENT (Preclinical)



The NLRP3 inhibitors MCC950 (25 mg/kg) and dapansutrile (60 mg/kg) protected against acute liver injury-related inflammation when administered before and 12 hours after exposure to the organic solvent N,N-Dimethylformamide (DMF) [31]. Pretreatment with these NLRP3 inhibitors mitigated the infiltration of macrophages and neutrophils into the liver, and suppressed the DMF-induced elevations of serum transaminases, and the pro-inflammatory cytokines IL-1 β and TNF- α . It is unclear whether these inhibitors would still confer benefit if administered after the onset of injury. Similar protective effects were observed in NLRP3 knockout animals.

Interstitial cystitis: POTENTIAL BENEFIT (preclinical)

Interstitial cystitis is characterized by sterile inflammation of the bladder, with unclear etiology. Activation of the NLRP3 inflammasome has been observed upon induction of interstitial cystitis in mice using cyclophosphamide [32]. Female (C57Bl/6) mice treated with dapansutrile (100 μ l of 100 mg/kg, orally) starting during the cyclophosphamide induction process had reduced inflammatory pathology in the bladder, including less infiltration of neutrophils, mast cells, CXCR3+CD8+ T cells, and dendritic cells, as well as lower levels of proinflammatory urinary cytokines and chemokines.

Foreign body response: POTENTIAL BENEFIT (preclinical)

Dapansutrile was found to protect against inflammation and fibrosis in response to the subcutaneous implantation of a foreign body (polycaprolactone scaffolds) in male mice (C57Bl/6) [33]. The scaffolds were implanted alone or with passively absorbed dapansutrile. The presence of dapansutrile with the scaffolds reduced early macrophage recruitment and suppressed late stage myofibroblast differentiation, resulting in decreased fibrotic encapsulation and increased vascularization. This suggests that dapansutrile may be a useful adjunct during the implantation of medical devices.

Safety: Not associated with adverse events in acute studies, but long-term studies with chronic dosing have not been conducted. Possible increased risk for infection.

Types of evidence:

- 6 clinical trials (3 RCT for topical gel formulation one Phase 1 in healthy adults, n=36 + two Phase 2 in osteoarthritis (n=79, n=202); Two trials for oral formulation one Phase 1 in healthy adults n=35, one Phase 2 in gouty arthritis n=29, one Phase 1b in heart failure n=30)
- Several laboratory studies

Dapansutril has been tested in six clinical trials (three for a topical formulation, and three for an oral capsule formulation), and according to the information disclosed by [Olatec Therapeutics](#), was found to exert a good safety profile. No treatment-emergent serious adverse events have been reported. In the Phase 1 study of the oral capsules in healthy adults (n=35), [2] all of the adverse events were determined to be unrelated to the drug and resolved spontaneously. There were no significant changes in hematological parameters, serum lipids, urinalysis, liver function enzymes, or physical examination measures with doses up to 1,000 mg for 8 days.

In patients with acute gout flares (n=29), there were no reported metabolic, physiological, or hematological changes, and all tested doses (up to 2000 mg/day for 8 days) were well-tolerated [17; 34]. The treatment-emergent adverse events were largely classified as metabolism and nutrition disorders (decreased appetite and hyponatraemia) and gastrointestinal disorders (constipation, diarrhea, nausea), however the majority of the former were related to gout flares, rather than the study drug.

In patients with NYHA II–III systolic heart failure (n=30), there were no clinically significant changes in chemistry and hematology laboratory parameters, including albumin, total protein, alanine aminotransferase (ALT), AST, bilirubin, lipase, BUN, creatinine, cystatin C, sodium, potassium, calcium, chloride, hematocrit, hemoglobin, red blood cell and white blood cell count with differential, and HbA1c for all tested doses (up to 2,000 mg/day for up to 14 days) [20]. The most common adverse events were an increase in lipase levels (3/8 at the 500 mg dose), and diarrhea (4/8 at the 2,000 mg dose). There were also no clinically relevant impacts to blood pressure, heart rate, or renal function, consistent with a good safety profile in this population.

In a preclinical study, treatment with dapansutril (up to ~1,000 mg/kg/day) for three months did not have any significant effects on basal synaptic transmission, synaptic plasticity (LTP), dendritic spine density, or performance on a task of spatial learning and memory (Morris water maze) in wild type (C57BL/6J) mice [8]. This suggests that, at least in the CNS, the therapeutic dosing range is likely to be wide enough to be compatible with clinical use.

The primary safety concern, which would not be captured by these short-term studies, is the risk for infection. The NLRP3 inflammasome is activated in response to numerous bacterial, fungal, and viral pathogens, and plays an important role in the inflammatory immune response toward these pathogens [1]. Consequently, chronic NLRP3 inhibition could lead to a dampened immune response toward this subset of pathogens, leading to an increased risk for chronic infections, or complications stemming from the inability to adequately clear these pathogens. While short-term administration during acute flares of

inflammation appears to be safe [34], it is not known at this time whether long-term administration of oral (systemic) dapansutril would lead to immune suppression, or additional adverse events.

Drug Interactions: Since NLRP3 is important for the production of IL-1 β it would be expected to have a similar drug-interaction profile with anti-IL-1 therapies, which has major interactions primarily with other therapeutic agents that target the immune system and could lead to immune suppression ([Drugs.com](https://www.drugs.com)).

Sources and dosing:

Dapansutril is being developed as OLT1177TM by [Olatec Therapeutics](https://www.olatec.com). It has not yet been approved for any indication, and continues to undergo clinical testing to determine doses that are both safe and clinically effective. Orally administered (capsules) dapansutril was found to be safe for acute administration up to 8 days in healthy adults at doses up to 1,000 mg per day. This dose led to drug plasma levels that were within the range of those associated with benefit in preclinical models. Due to the relatively long half-life (~24 hours), there is accumulation of the drug with consecutive daily dosing [2]. In patients with gout or heart failure, dapansutril was well-tolerated at oral doses up to 2,000 mg/day for 8 to 14 days.

Research underway:

According to [Clinicaltrials.gov](https://clinicaltrials.gov), there are currently four active clinical trials for dapansutril.

Dapansutril is being tested in a Phase 1/2 trial in combination with pembrolizumab (anti-PD-1) in patients with PD-1 refractory advanced melanoma ([NCT04971499](https://clinicaltrials.gov/ct2/show/study/NCT04971499)). This open-label study has an expected completion date in 2025.

Dapansutril is being tested in the Phase 2 Dapan-Dia trial (estimated n=300) in patients with type 2 diabetes and diabetes-related vascular complications ([NCT06047262](https://clinicaltrials.gov/ct2/show/study/NCT06047262)). It will be tested at a dose of 1,000 mg/day (500 mg BID) for 26 weeks, and the study has an estimated completion date in 2026.

Dapansutril is being tested in a randomized, double-blind, placebo-controlled Phase 2/3 trial (estimated n=300) in patients with acute gout flare ([NCT05658575](https://clinicaltrials.gov/ct2/show/study/NCT05658575)). Participants will receive an initial



loading dose of 2,000 mg dapansutrine, and then a maintenance regimen of 1,000 mg twice daily for the remainder of the 7 days. The study has an expected completion date in 2025.

Dapansutrine will be tested in an early Phase 1 study in which advanced cardiovascular imaging is performed on patients following an urgently reperfused type I myocardial infarction to assess the systemic effects of inflammasome activation following treatment with dapansutrine or placebo ([NCT05880355](#)). The primary outcome is carotid plaque volume change over six months, while secondary outcome measures assess plaque inflammatory activity and coronary microvascular function. The study has an expected completion date in 2028.

A planned Phase 3 trial for covid-19 with cytokine release syndrome was terminated due to the widespread use of vaccinations and other therapeutics, which prevented the recruitment of a suitable patient population([NCT04540120](#)). Similarly, a planned pilot Phase 2 trial in patients with Schnitzler Syndrome was terminated because of issues with the study design that did not allow for determination of efficacy and safety in patients who were currently well controlled on anakinra (anti-IL-1) therapy ([NCT03595371](#)).

Search terms:

Pubmed, Google: Dapansutrine, OLT1177 +

- NLRP3, neurodegeneration, aging, arthritis, inflammation, cardiovascular, safety, clinical trials

Websites visited for Dapansutrine (OLT1177):

- [Clinicaltrials.gov](#)
- [PubChem](#)
- [IUPHAR/BPS Guide to Pharmacology](#)

References:

1. Swanson KV, Deng M, Ting JPY (2019) The NLRP3 inflammasome: molecular activation and regulation to therapeutics. *Nature Reviews Immunology* **19**, 477-489<https://doi.org/10.1038/s41577-019-0165-0>.
2. Marchetti C, Swartzwelter B, Gamboni F *et al.* (2018) OLT1177, a β -sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. *Proc Natl Acad Sci U S A* **115**, E1530-E1539<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816172/>.
3. Tosato G (1990) Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. *Blood* **75**, 1305-1310<https://pubmed.ncbi.nlm.nih.gov/2310829/>.



4. Song L, Pei L, Yao S *et al.* (2017) NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies. *Front Cell Neurosci* **11**, 63-63 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343070/>.
5. Sfera A, Gradini R, Cummings M *et al.* (2018) Rusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease. *Front Neurol* **9**, 1062-1062 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288235/>.
6. Griffin WS, Stanley LC, Ling C *et al.* (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. *Proc Natl Acad Sci U S A* **86**, 7611-7615 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC298116/>.
7. Forlenza OV, Diniz BS, Talib LL *et al.* (2009) Increased Serum IL-1 β Level in Alzheimer's Disease and Mild Cognitive Impairment. *Dementia and Geriatric Cognitive Disorders* **28**, 507-512 <https://www.karger.com/DOI/10.1159/000255051>.
8. Lonnemann N, Hosseini S, Marchetti C *et al.* (2020) The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* **117**, 32145-32154 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749353/>.
9. Amo-Aparicio J, Garcia-Garcia J, Puigdomenech M *et al.* (2022) Inhibition of the NLRP3 inflammasome by OLT1177 induces functional protection and myelin preservation after spinal cord injury. *Experimental Neurology* **347**, 113889 <https://www.sciencedirect.com/science/article/pii/S0014488621002971>.
10. Sánchez-Fernández A, Skouras DB, Dinarello CA *et al.* (2019) OLT1177 (Dapansutrile), a Selective NLRP3 Inflammasome Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis Pathogenesis. *Frontiers in Immunology* **10** <https://www.frontiersin.org/article/10.3389/fimmu.2019.02578>.
11. Fahey E, Doyle SL (2019) IL-1 Family Cytokine Regulation of Vascular Permeability and Angiogenesis. *Frontiers in Immunology* **10** <https://www.frontiersin.org/article/10.3389/fimmu.2019.01426>.
12. Amo-Aparicio J, Daly J, Højen JF *et al.* (2023) Pharmacologic inhibition of NLRP3 reduces the levels of α -synuclein and protects dopaminergic neurons in a model of Parkinson's disease. *Journal of neuroinflammation* **20**, 147 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286423/>.
13. Fang M, Xia F, Wang J *et al.* (2024) The NLRP3 inhibitor, OLT1177 attenuates brain injury in experimental intracerebral hemorrhage. *International immunopharmacology* **131**, 111869 <https://pubmed.ncbi.nlm.nih.gov/38492343/>.
14. Tubach F, Ravaud P, Martin-Mola E *et al.* (2012) Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. *Arthritis Care & Research* **64**, 1699-1707 <https://onlinelibrary.wiley.com/doi/abs/10.1002/acr.21747>.
15. Tang L, Sim I, Moqbel S *et al.* (2022) Dapansutrile ameliorated chondrocyte inflammation and osteoarthritis through suppression of MAPK signaling pathway. *Human & experimental toxicology* **41**, 9603271221145401 <https://pubmed.ncbi.nlm.nih.gov/36508695/>.
16. Marchetti C, Swartzwelter B, Koenders MI *et al.* (2018) NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. *Arthritis Res Ther* **20**, 169-169 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091035/>.
17. Klück V, Jansen TLTA, Janssen M *et al.* (2020) Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. *Lancet Rheumatol* **2**, e270-e280 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523621/>.

18. Klück V, Janssen M, Jansen T *et al.* (2019) P159/O30 OLT1177™, an oral NLRP3 inflammasome inhibitor, inhibits acute joint inflammation and circulating IL 1 β during gout flares in humans. *Annals of the Rheumatic Diseases* **78**, A69-A69 https://ard.bmj.com/content/annrheumdis/78/Suppl_1/A69.2.full.pdf.
19. Butts B, Gary RA, Dunbar SB *et al.* (2015) The Importance of NLRP3 Inflammasome in Heart Failure. *J Card Fail* **21**, 586-593 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516025/>.
20. Wohlford GF, Van Tassell BW, Billingsley HE *et al.* (2020) Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure. *Journal of cardiovascular pharmacology* **77**, 49-60 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774821/>.
21. Toldo S (2019) The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse. *Journal of cardiovascular pharmacology* **73**, 215-222 <https://pubmed.ncbi.nlm.nih.gov/30747785/>.
22. Aliaga J, Bonaventura A, Mezzaroma E *et al.* (2021) Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177^(®) (Dapansutrile) in a Mouse Model of Severe Ischemic Cardiomyopathy Due to Non-Reperused Anterior Wall Myocardial Infarction. *Molecules* **26**, 3534 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227554/>.
23. Yang H, Zhu J, Fu H *et al.* (2024) Dapansutrile Ameliorates Atrial Inflammation and Vulnerability to Atrial Fibrillation in HFpEF Rats. *Heart, lung & circulation* **33**, 65-77 <https://pubmed.ncbi.nlm.nih.gov/38040503/>.
24. Tengesdal IW, Menon DR, Osborne DG *et al.* (2021) Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. *Proc Natl Acad Sci U S A* **118**, e2000915118 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958415/>.
25. Tengesdal IW, Dinarello A, Powers NE *et al.* (2021) Tumor NLRP3-Derived IL-1 β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression. *Frontiers in immunology* **12**, 661323-661323 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438323/>.
26. Dinarello A, Mills TS, Tengesdal IW *et al.* (2023) Dexamethasone and OLT1177 Cooperate in the Reduction of Melanoma Growth by Inhibiting STAT3 Functions. *Cells* **12** <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856388/>.
27. Amo-Aparicio J, Dominguez A, Atif SM *et al.* (2023) Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. *Cancer research communications* **3**, 1899-1911 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510589/>.
28. Saber S, Youssef ME, Sharaf H *et al.* (2021) BBG enhances OLT1177-induced NLRP3 inflammasome inactivation by targeting P2X7R/NLRP3 and MyD88/NF- κ B signaling in DSS-induced colitis in rats. *Life Sciences* **270**, 119123 <https://www.sciencedirect.com/science/article/pii/S0024320521001089>.
29. Lunding LP, Skouras DB, Vock C *et al.* The NLRP3 inflammasome inhibitor, OLT1177[®], ameliorates experimental allergic asthma in mice. *Allergy* **n/a** <https://onlinelibrary.wiley.com/doi/abs/10.1111/all.15164>.
30. Elsayed MS, Abu-Elsaad NM, Nader MA (2021) The NLRP3 inhibitor dapansutrile attenuates folic acid induced nephrotoxicity via inhibiting inflammasome/caspase-1/IL axis and regulating autophagy/proliferation. *Life Sciences* **285**, 119974 <https://www.sciencedirect.com/science/article/pii/S0024320521009619>.



31. Zhang XN, Zhang YJ, Wang L *et al.* (2024) NLRP3 inflammasome activation triggers severe inflammatory liver injury in N, N-dimethylformamide-exposed mice. *The Science of the total environment* **929**, 172653 <https://pubmed.ncbi.nlm.nih.gov/38649053/>.
32. Kiran S, Rakib A, Singh UP (2022) The NLRP3 Inflammasome Inhibitor Dapansutrile Attenuates Cyclophosphamide-Induced Interstitial Cystitis. *Front Immunol* **13**, 903834 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205468/>.
33. Chan AHP, Xu XS, Chin IL *et al.* (2024) Dapansutrile OLT1177 suppresses foreign body response inflammation while preserving vascularisation of implanted materials. *Journal of materials chemistry B* **12**, 7334-7347 <https://pubmed.ncbi.nlm.nih.gov/38973614/>.
34. Jansen T, Klück V, Janssen M *et al.* (2019) P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile™ (OLT1177™), in acute gout. *Annals of the Rheumatic Diseases* **78**, A70-A71 https://ard.bmj.com/content/annrheumdis/78/Suppl_1/A70.full.pdf.

Disclaimer: Cognitive Vitality Reports® do not provide, and should not be used for, medical advice, diagnosis, or treatment. You should consult with your healthcare providers when making decisions regarding your health. Your use of these reports constitutes your agreement to the [Terms & Conditions](#).

If you have suggestions for drugs, drugs-in-development, supplements, nutraceuticals, or food/drink with neuroprotective properties that warrant in-depth reviews by ADDF's Aging and Alzheimer's Prevention Program, please contact INFO@alzdiscovery.org. To view our official ratings, visit [Cognitive Vitality's Rating page](#).